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Structured abstract 88 
Background:  Screening for renal cell carcinoma (RCC) has been identified as a key research 89 
priority; however, no randomised control trials have been performed. Value of information 90 
analysis can determine whether further research on this topic is of value. 91 
 92 
Objectives: To determine (a) whether current evidence suggests screening is potentially 93 
cost-effective. If so, (b) in which age/sex groups, (c) identify evidence gaps and (d) estimate 94 
the value of further research to close those gaps.  95 
 96 
Design, Setting, Participants: A decision model was developed evaluating screening in 97 
asymptomatic individuals in the UK. A National Health Service perspective was adopted. 98 
 99 
Intervention: A single focused renal ultrasound scan compared with standard of care (no 100 
screening). 101 
 102 
Outcome measures: Expected lifetime costs, quality adjusted life years (QALYs) and 103 
incremental cost-effectiveness ratio (ICER), discounted at 3.5%/annum. 104 
 105 
Results: Given a prevalence of RCC of 0.34% (0.18-0.54%), screening 60 year-old men 106 
resulted in an ICER of £18,092/QALY[€22,843/QALY]. Given a prevalence of RCC of 0.16% 107 
(0.08-0.25%), screening 60-year-old women resulted in an ICER of 108 
£37,327/QALY[€47,129/QALY]. In the one-way sensitivity analysis, the ICER was 109 





at age 60 years. Given a willingness to pay threshold of £30,000/QALY[€37,878/QALY], the 111 
population expected value of perfect information was £194 million[€244 million] 112 
and £97 million[€123 million] for 60-year-old men and women respectively. The expected 113 
value of perfect parameter information suggests the prevalence of RCC and stage shift 114 
associated with screening are key research priorities. 115 
 116 
Conclusion: Current evidence suggests one-off screening of 60-year old men is potentially 117 
cost-effective and that further research into this topic would be of value to society. 118 
 119 
Patient Summary: Economic modelling suggests that screening 60-year-old men for kidney 120 
cancer using ultrasound may be a good use of resources and that further research on this 121 
topic should be performed.  122 
 123 
 124 








Cost-effectiveness analyses (CEA) are classically performed to aid decisions regarding the 129 
value of implementing new interventions into a health service. More recently, value of 130 
information analyses (VOI) of screening interventions have been undertaken using the 131 
currently available evidence, prior to a large trial being undertaken, aiming to determine the 132 
value of investing future funds into further research[1]. Indeed, VOI has been used to 133 
examine uncertainty surrounding the optimal screening strategy for colorectal cancer and 134 
therefore prioritise future research efforts[2].  135 
 136 
Screening for renal cell carcinoma (RCC) has repeatedly been identified as a research 137 
priority[3-6]. Over a quarter of individuals diagnosed with RCC have metastases at 138 
presentation. Five-year age standardized relative survival for these individuals is 6% 139 
compared to 84% for those with stage I disease[7]. Ultrasound has been proposed as a 140 
screening tool, as it is well tolerated, inexpensive and widely available[8]. National 141 
abdominal aortic aneurysm (AAA) screening programs for 65-year-old men are established 142 
in the UK and Sweden and have demonstrated that an ultrasound-based screening program 143 
can be delivered in the community by trained technicians[9, 10]. Observational studies 144 
evaluating screening for RCC using ultrasound have been conducted. However, none were 145 
randomised, and all were published more than a decade ago[11-18]. Due to the relatively 146 
low prevalence of RCC in unselected asymptomatic individuals, a randomised controlled trial 147 
(RCT) sufficiently powered to detect an impact on survival would need to recruit hundreds 148 





currently available evidence, with the aim of determining the value of performing further 150 








Scope of the decision model 155 
 156 
A cohort simulation model was developed adopting a UK National Health Service 157 
perspective, consistent with Consolidated Health Economic Evaluation Reporting Standards 158 
(Supplement)[19, 20]. The model compares screening (intervention) versus the standard of 159 
care (no screening) in asymptomatic individuals from the general population. Screening 160 
consists of a single focused renal ultrasound, delivered by technicians in the community, 161 
similar to AAA screening[21]. If the ultrasound is reported as normal or as a simple cyst, the 162 
patient is discharged. Any other abnormality is investigated with an outpatient urology clinic 163 
± CT as appropriate (Supplemental Figure 1). The primary outcomes are the incremental 164 
costs (2016 £GBP), incremental quality adjusted life years (QALYs) and incremental cost-165 
effectiveness ratio (ICER) comparing one-off screening with no screening. The ICER was 166 
defined as the mean incremental costs divided by the mean incremental QALYs. A cycle 167 
length of one year and a lifetime time horizon were adopted. Costs and QALYs were 168 
discounted at 3.5%/annum. The UK willingness to pay threshold of £20,000-£30,000/QALY 169 
gained [€25,252-€37,878/QALY] was used; therefore, an ICER>£30,000 was considered not 170 
to be cost-effective [19, 20].  171 
 172 
Model structure 173 
 174 
The model, which consisted of a decision tree with Markov models at each terminal node, 175 
was developed in Microsoft Excel (2016). The decision tree demonstrates the disease status 176 





positive/negative). Figure 1 represents a simplified schematic of the Markov models 178 
(Supplemental Figures 2-7). 179 
 180 
Model inputs 181 
 182 
Model inputs were derived through comprehensive literature reviews and where no data 183 
were available, through structured expert elicitation (Table 1) [8, 11, 22, 23].  Further details 184 
are available in the Supplemental Methods. 185 
A meta-analysis demonstrated that the pooled prevalence of RCC detected by ultrasound 186 
was more than twice as high in studies from Europe and North America compared to Asia 187 
(0.17% (0.09-0.27%) vs 0.06 (0.03-0.09%)) (n=29,938)[11]. Only one study, by Mihara et al., 188 
reported the prevalence of RCC by age and sex, which screened Japanese individuals from 189 
1983 to 1996 (overall prevalence of RCC: 0.09%)[14]. Although the study by Mihara et al. 190 
underestimates the true prevalence of RCC in a contemporary Western population, the 191 
relative prevalence by age and sex is likely to still be relevant[11, 14, 24]. Therefore, to 192 
derive likely prevalence rates in the UK by age and sex, the prevalence reported by Mihara 193 
et al. was used along with the results of the meta-analysis applied to the UK population 194 
reported by the Office for National Statistics (Table 1)[25]. 195 
 196 
The cost of AAA screening ultrasound in the UK is £37.53 [€47] [21]. In the base case, it was 197 
assumed screening renal ultrasound would have the same cost (Table 1). If ultrasound were 198 
to be performed by sonographers in secondary care, then it would be priced at £55 (IQR 199 






No studies have evaluated the impact of screening for RCC on quality of life (QoL)[22]. 202 
Ultrasound screening for AAA and ovarian cancer was not associated with a disutility[27-31]. 203 
Therefore, ultrasound screening for RCC was assigned a disutility of 0 and this assumption 204 
was tested in the sensitivity analysis. 205 
 206 
Model analysis 207 
 208 
The decision model was run with 3000 Monte Carlo simulations as this achieved stability of 209 
results, defined as a coefficient of variation <2% for the SE of the incremental net monetary 210 
benefit[32]. In brief, this means a set of inputs was sampled from the respective 211 
distributions, the model calculated and repeated 3000 times to generate an empirical 212 
estimate of the uncertainty in cost-effectiveness. The ICER was evaluated for males and 213 
females aged 40, 50 and 60 years as estimates for prevalence of RCC were available for 214 
these groups based on the study by Mihara et al[14]. The population in whom screening is 215 
most cost-effective was determined from this and used as the base case for all subsequent 216 
analyses.  217 
 218 
The expected value of perfect information (EVPI) and perfect parameter information (EVPPI) 219 
were determined. The EVPI summarises the value of eliminating all parameter uncertainty 220 
(i.e. perfect information), whereas the EVPPI summarises the value of eliminating individual 221 
parameter uncertainty[33, 34]. Thus, the EVPI provides an upper limit for all future research 222 
expenditure regarding the decision problem. The EVPPI determines the value of eliminating 223 





priorities[34]. The population VOI statistics were based on the number individuals eligible 225 
for screening[35]. The EVPPI was determined by running the simulation 1000 times for the 226 
inner loop and 2000 times for the outer loop. An approximation of the impact of screening 227 
was obtained by multiplying the incremental cost and QALYs of screening (per patient) by 228 








Determining the most cost-effective screening population 233 
 234 
The point estimate ICER is <£30,000/QALY for 50-year-old men and <£20,000/QALY for 60-235 
year-old men (Table 2). The ICER is >£30,000/QALY for women of all ages, however the most 236 
favourable ICER is observed for 60-year-old women. Therefore, age 60 years (males and 237 
females) was chosen as the base case for all subsequent analyses.  238 
 239 
Analysis of uncertainty 240 
 241 
For 60-year-old males, there is a 62% probability that the ICER is <£20,000/QALY and a 66% 242 
probability that the ICER is <£30,000/QALY. For 60-year-old females, there is a 44% 243 
probability that the ICER is <£20,000/QALY and a 56% probability that the ICER is 244 
<£30,000/QALY (Supplemental Figure 8). 245 
 246 
Sensitivity analyses 247 
 248 
Cost-effectiveness improves as the prevalence increases and the cost of ultrasound 249 
decreases (Table 3). Using £37[€47] as the cost of ultrasound, the ICER remains 250 
<£30,000/QALY so long as the prevalence of RCC is ≥0.25% for men and ≥0.2% for women 251 
aged 60 years. Using our current estimates for the prevalence of RCC for 60-year-old 252 
women, the ICER is <£30,000/QALY if the cost of screening ultrasound was reduced from 253 





For 60-year-old males, the ICER remains <£30,000/QALY so long as the disutility associated 255 
with screening is 0.05 for one week (Supplemental Table 6). The ICER is <£30,000/QALY, if 256 
the specificity of ultrasound is ≥85% (Supplemental Table 7). Furthermore, in the base case, 257 
it was assumed that the combined prevalence of incidental benign conditions detected by 258 
screening would be 2.7%[11, 17, 18]. The sensitivity analysis demonstrated that in 60-year-259 
old men, the ICER remains <£30,000/QALY so long as the combined prevalence of other 260 
incidentally detected renal conditions is 20% (Supplemental Table 8). Sensitivity analyses 261 
for 60-year-old females are available in Supplemental Tables 6-8. 262 
 263 
Value of information analysis 264 
 265 
The number of individuals aged 60 years eligible to receive screening in the UK is 362,766 266 
men/annum and 374,008 women/annum. Assuming a time horizon for which additional 267 
information is useful of ten years, this equates to a population that may benefit from 268 
screening of 3,122,576 men and 3,219,344 women (discounted at 3.5%)[36]. Given a 269 
willingness to pay threshold of £30,000/QALY, the population EVPI is £244,415,131 270 
[€209,133,931] and £97,263,108 [€122,804,400] for 60-year-old males and females 271 
respectively (Supplemental Figure 9). The three parameters with the highest population 272 
EVPPI are the prevalence of RCC, the stage distribution of screen detected disease and the 273 








Impact on health services 278 
 279 
Compared with no screening, screening 60-year-old males results in an overall expected 280 
incremental cost per patient of £44.55 (cost of screening and treatment, discounted to 281 
present value) over a 30-year lifetime[€56]. The number of males eligible to receive 282 
screening in the UK is 362,766 per annum. Therefore, the present-value cost to the health 283 
service would be £16 million[€20 million] per cohort screened, over 30 years. However, the 284 
majority of screening costs are accrued up front when screening occurs. The expected 285 
incremental QALYs per patient is 0.0025 over 30 years (discounted to present value). 286 
Therefore, that equates to 893 QALYs gained per cohort screened. For 60-year-old women, 287 
screening would cost £17 million[€21 million] and would lead to 467 additional QALYs per 288 






Screening for RCC has the potential to improve survival outcomes[4, 5]. However, as with 292 
any screening program, there is also a potential for harm, including over-diagnosis, as well 293 
as psychological and economic implications for patients and society. No RCTs of screening 294 
for RCC have been undertaken[8]. We demonstrate that the population EVPI is £194 million 295 
and £97 million for 60-year-old men and women respectively. This suggests further research 296 
is likely to be of good value to the funder, and should be focused on estimating the 297 
prevalence of RCC and the stage shift associated with screening.   298 
 299 
Determinants of cost-effectiveness 300 
 301 
Using current evidence, this decision model suggests screening may be cost-effective in 302 
males but not females, due to lower prevalence of RCC in the latter[11, 14]. The true 303 
prevalence of RCC by age/sex in the UK is unknown. Sensitivity analysis suggests that 304 
screening may be cost-effective if the prevalence is 0.25% for males and 0.2% for 305 
females. A meta-analysis demonstrated the prevalence of RCC detected in middle-aged 306 
Americans undergoing screening CT is 0.21%[24]. Once again, the prevalence was not 307 
reported by age/sex, however it may indeed be above the threshold identified by our 308 
sensitivity analysis. Although beyond the scope of the present analysis, risk-stratified 309 
screening may increase cost-effectiveness by targeting screening towards individuals with a 310 
higher prevalence. At present there is a lack of specific, validated models to predict the risk 311 
of RCC and further research is required to elucidate this[8, 37]. Similarly, screening for AAA 312 




prevalence of the disease[28, 38]. However, there are important equity considerations 314 
associated with screening only one sex[39]. 315 
 316 
The cost of screening ultrasound is a modifiable factor which is a major determinant of cost-317 
effectiveness. Screening 60-year-old males remains cost-effective so long as the cost of 318 
ultrasound is <£60. This is very likely as it is below the current cost of ultrasound performed 319 
by a sonographer in secondary care[26]. When screening 60y females, the ICER drops 320 
<£30,000/QALY when the cost of ultrasound is reduced from £37 to £30. It is unclear 321 
whether the cost of technician-performed ultrasound may be reduced to this level. Renal 322 
ultrasound is technically more challenging to perform than aortic ultrasound. Accuracy is 323 
dependent on the size of the renal lesion and operator experience[40-42]. Our model 324 
suggests screening 60-year-old males remains cost-effective (i.e. ICER< £30,000) so long as 325 
the specificity of ultrasound is ≥85%, and the prevalence of benign incidental findings at 326 
ultrasound is ≤20%. All these conditions seem likely. 327 
 328 
Potential harms of screening 329 
 330 
Evidence on the impact of screening for RCC on QoL is lacking[8, 22]. In the base case, it was 331 
assumed that undergoing screening ultrasound was not associated with a disutility, and this 332 
may contribute to the results demonstrating that the EVPPI for utilities was £0. However, in 333 
the sensitivity analysis, we showed that for 60-year-old men if the disutility associated with 334 
screening renal ultrasound is ≥0.05 for one week, screening is no longer cost-effective. This 335 
is because a small reduction in utility would be applied to such a large number of individuals 336 




which RCC is detected. Therefore, it is essential that any future RCC screening studies 338 
evaluate the impact of screening on QoL. 339 
 340 
Strengths and limitations 341 
 342 
A strength of this work is that it is the first decision analysis of screening for RCC in 343 
asymptomatic individuals. The model was designed with input from a multidisciplinary team 344 
of RCC experts and a patient advocate. Importantly, the model incorporates the impact of 345 
incidental findings detected by screening on cost-effectiveness. Systematic reviews were 346 
undertaken to determine key model inputs and where data were not available, structured 347 
expert elicitation was performed[8, 11, 22, 23]. This ensures that uncertainty surrounding 348 
parameter estimates was captured accurately, enabling reliable VOI[35].   349 
 350 
The model represents a simplification of reality and shares some limitations inherent to all 351 
CEAs. Due to structural assumptions within the model, it was not appropriate to assess the 352 
impact of ultrasound sensitivity on the ICER, as the stage distribution of false positives was 353 
determined by evidence from the literature. Some CEAs in other disease areas have 354 
overcome this by modelling the natural history of undiagnosed disease[32]. However, there 355 
are no existing data on the transition probabilities between undiagnosed RCC stages. As 356 
there are eleven potential health states (diagnosed and undiagnosed stage I T1a, I T1b, II, III, 357 
IV, death) this would require 20 transition probabilities to be derived through expert 358 
elicitation. This would introduce undue uncertainty in the decision analysis, therefore it was 359 
felt that the current structure was the most appropriate. High profile CEAs in other disease 360 




to minimize the assumptions and uncertainties arising from lack of data[43]. Life table 362 
models and discrete event simulation models of screening for breast cancer have achieved 363 
similar results[43, 44]. 364 
 365 
The CEA is limited by the absence of trial level data regarding certain model inputs. 366 
Conversely, a major indication for the CEA was to determine if undertaking a trial of 367 
screening was warranted on economic grounds. The prevalence of RCC was reported for a 368 
limited number of age groups[11, 14]. It was not possible to evaluate repeated screening at 369 
regular intervals, as screening studies scanned individuals only once. The model assumes 370 
that cancer-specific mortality is determined by RCC stage and is the same in the screening 371 
and no screening cohorts. Individuals with incidentally detected tumours have significantly 372 
better survival compared to symptomatic patients, after adjusting for tumour grade and 373 
stage[45]. Therefore, the model may underestimate the benefit of screening[46, 47]. 374 
However, as there are no RCTs demonstrating the effectiveness of screening, we do not 375 
know if screening in a contemporary population would lead to a stage shift nor whether it 376 
would impact survival. This consideration is particularly important as the number of 377 
individuals undergoing abdominal imaging for other indications is rising[48]. Further trial 378 
level data are required to quantify overdiagnosis and lead time bias.  Additionally, there 379 
were few data on the prevalence of benign incidental findings at screening, and their 380 
associated impact on QoL or cost. We assigned a cost but no gain or loss of QALYs from 381 
incidental findings. This simplification may underestimate the cost-effectiveness of 382 







Given the available evidence and the current willingness to pay threshold, our model 387 
suggests that screening may be cost-effective in 60-year-old males. The prevalence of RCC 388 
by age/sex is a major determinant of cost-effectiveness and represents a key research 389 
priority, along with the stage shift associated with screening. Future work should focus on 390 
evaluating the potential harms of screening including the impact on QoL, incidental findings 391 


















Figure 1: Structure of the Markov model  407 
Figure 1 represents a simplified schematic of the Markov models; further details can be 408 
found in the Supplement. In brief, individuals without RCC can have a number of benign 409 
incidental findings (asymptomatic calculi, hydronephrosis etc). Individuals with RCC can be 410 
undiagnosed or diagnosed, by one of two ways: diagnosed via screening or opportunistically 411 
within the health service. Once RCC is diagnosed, individuals can be classified into one of the 412 
following five RCC health states: stage I T1a, stage I T1b, stage II, stage III and stage IV 413 
based on established AJCC staging criteria. Newly diagnosed (ND) health states are tunnel 414 
states reflecting costs and QALYs associated with the first year of diagnosis and treatment of 415 
RCC, with follow up costs accrued and discounted up front, as previously described [49]. 416 
These tunnel states will transition into long-term health states, which represent metastasis 417 
free (MF) states. Individuals will remain in each of these MF states until they progress (i.e. 418 
metastatic progression). Stage IV disease (shown in the dotted box) encompasses both newly 419 
diagnosed stage IV and metastatic recurrence. Stage IV disease may be subdivided into one 420 
of the following health states based on treatment: individuals with no progression (NP) on 421 
first line systemic therapy (“Stage IV, NP 1st line ST”) and those with who do not receive 422 
systemic therapy (“Stage IV, no ST”). These can lead to no progression on second line 423 
therapy (“Stage IV, NP 2nd line ST”), no progression on third line therapy (“Stage IV, NP 3rd 424 
line ST”), or progressive disease (“Stage IV, PD”). All health states can lead to “non RCC 425 
death” (i.e. background mortality) or “RCC death” via the “Terminal” tunnel health state, 426 
representing costs associated with the final year of life [49]. Arrows to these death health 427 




























































Figure 2: Population expected value of perfect parameter information 437 
The population expected value of perfect parameter information (EVPPI) at a willingness to 438 
pay threshold of £30,000/QALY is shown for males and females aged 60 years. The 439 
parameters investigated were: screening parameters, costs, utilities, transition probabilities 440 
(TP) and stage distribution (SD) i.e. the proportion of individuals with RCC in each cancer 441 
stage. The “% receiving each therapy” refers to the proportion of individuals with RCC who 442 
undergo each management option, for example, ablation, active surveillance, surgery (open 443 
vs laparoscopic, partial vs radical) etc. “Utilities” refers to all utilities in the model, not just 444 
the utility associated with screening. Note, the EVPPIs do not sum to the EVPI due to 445 
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Table 1: Model inputs 451 
For each model input, the mean estimate along with the 95% confidence interval (CI) or 452 
standard error (SE) is shown. For costs, the interquartile range (IQR) is reported as this is the 453 
data provided by the national schedule of referencing costs. Parameters of the distribution 454 
used in the probabilistic sensitivity analysis are demonstrated. For parameters derived 455 
through expert elicitation, the median estimate and 95% credibility intervals (CrI) are shown. 456 
For modified Connor Mosimann distributions (mCM), the a, b, L, U parameters are shown. 457 
Medians do not sum to 1, however means do (data not shown). The ordering of Zed 458 
parameters is critical to ensure correct calculation of probabilities, although this order may 459 
not be the same as the logical order (stages I-IV). Further details regarding how transition 460 
probabilities and summary costs were derived are available in the Supplement. 461 
 462 
Parameter Source Mean (95% CI) Distribution 
Screening parameters    
Sensitivity of ultrasound [16, 17, 50, 51] 81.8% (52.3%-94.9%) Beta (9,2) 
Specificity of ultrasound [16, 17] 98.2% (97.9%-98.5%) Beta (9771, 177) 
Specificity of CT following a positive 
ultrasound 
[17] 98.9% (96.0%-99.7%) Beta (175,2) 
Prevalence of asymptomatic 
hydronephrosis 
[11] 0.48% (0.21-0.87%) Beta (8.05, 1654.60) 
Prevalence of asymptomatic stones [11] 1.82% (0.59-3.64%) Beta (5.03, 275.51) 
Prevalence of other benign 
asymptomatic findings on screening~ 
[17, 18] 0.40% (0.30%-0.55%) Beta (40, 9919) 
    
Prevalence of RCC    
Prevalence in 40-year-old males 
Adapted from 
[11, 14, 25] 
0.14% (0.08-0.23%) Beta (14.24, 9780.69) 
Prevalence in 50-year-old males 0.23% (0.12-0.37%) Beta (12.58, 5502.85) 
Prevalence in 60-year-old males 0.34% (0.18-0.54%) Beta (13.17, 3905.89) 
Prevalence in 40-year-old females 0.07% (0.04-0.11%) Beta (15.49, 21892.72) 
Prevalence in 50-year-old females 0.09% (0.05-0.14%) Beta (14.97, 16729.45) 
Prevalence in 60-year-old females 0.16% (0.08-0.25%) Beta (12.30, 8011.51) 
    
    
Stage distribution    




Screen detected RCC    
Stage I T1a [11] 45.45% (34.0%-57.4%)* 
Dirichlet (30, 27, 9) Stage I T1b [11] 40.91% (29.9%-53.0%)* 
Stage II [11] 13.64% (7.3%-23.9%)* 
 [11]   
Stages I-II [11] 84.39% (78.8%-88.7%) 
Dirichlet (173, 28 ,4) 
 
Stage III [11] 13.66% (9.6%-19.0%) 
Stage IV [11] 1.95% (0.8%-4.9%) 
    
RCC detected by the health service    
Stage I T1a [52] 55.58% (54.12%-57.0%)# Beta (2511, 2007) 
Stage I T1b [52] 44.42% (43.0%-45.9%) # Beta (2007,2511) 
    




Stages II [53] 9.54% (8.83%-10.31%) 
Stage III [53] 18.42% (17.47%-19.42%) 
Stage IV [53] 27.83% (26.72%-28.97%) 
    
Stage distribution of false positives    
Stage I T1a [54-56] 60.7% (57.1%-64.1%) 
Dirichlet (451, 168, 124) 
 
Stage I T1b [54-56] 22.6% (19.7%-25.8%) 
Stages II [54-56] 16.7% (14.2%-19.5%) 
Stage III [54-56] 0%  
Stage IV [54-56] 0%  
    
    
False negatives at screening    





76% (43%-95%) mCM (6.72, 2.41, 0, 1) 
Stage I T1b 9% (1%-44%) mCM (0.35, 0.49, 0.157, 1) 
Stage IV 4% (0-32%) mCM (0.64, 0.40, 0, 1) 
Stage II 1% (0%-14%) mCM (10, 10, 0, 1) 
Stage III 1% (0%-14%) mCM (-) 
    
Annual transition probabilities    
Parameter Source Mean (95% CI) Distribution 
Stage I T1a    
Stage I T1a > Stage I T1a  
1-sum of other 
probabilities 
 
Stage I T1a > Stage IV [57] 0.0110 (0.00552, 0.0183) Beta (11.04, 991.96) 
Stage I T1a > RCC death [58] 0.00424 (0.00346,0.00509) Beta (102.80, 24165.20) 
    
Stage I T1b    
Stage I T1b > Stage I T1b  
1-sum of other 
probabilities 
 
Stage I T1b > Stage IV [57] 0.0326 (0.0216-0.0457) Beta (26.91, 799.11) 
Stage I T1b > RCC death [58] 0.0198 (0.0178-0.0219) Beta (349.31, 17322.70) 
    
Stage II    
Stage II > Stage II  
1-sum of other 
probabilities 
 
Stage II > Stage IV [57] 0.0538 (0.0371, 0.0733) Beta (31.85, 560.15) 
Stage II > RCC death [7] 0.0306 (0.0131-0.0544)** Beta (7.86, 250.99) 
    
Stage III    
Stage III > Stage III  
1-sum of other 
probabilities 
 
Stage III > Stage IV [57] 0.104 (0.0810,0.129) Beta (64.69, 559.31) 
Stage III > RCC death [7] 0.105 (0.0828-0.131)** Beta (64.88, 547.54) 
    
 
 




No progression (NP) on 1st line 
therapy 
NP on 1st line therapy> NP on 1st line 
therapy 
[59] 0.274 (0.242-0.307) 
Dirichlet (201, 181, 351) NP on 1st line therapy> progressive 
disease 
[59] 0.247 (0.216-0.278) 
NP on 1st line therapy> death$ [59] 0.479 (0.443-0.515) 
    
No progression (NP) on 2nd line 
therapy 
   
NP on 2nd line therapy> NP on 2nd line 
therapy 
[60] 0.186 (0.162- 0.211) Beta (177.04, 775.96) 
NP on 1st line therapy> progressive 
disease 
 
1-sum of other 
probabilities 
 
NP on 1st line therapy> death$ [61] 0.595 (0.577-0.613) Beta (1739.46, 1182.54) 
    
No progression (NP) on 3rd line 
therapy 
   
NP on 3rd line therapy> NP on 3rd line 
therapy 
 
1-sum of other 
probabilities 
 
NP on 3rd line therapy> progressive 
disease 
[62, 63] 0.451 (0.420-0.482) Beta (447.56, 545.44) 
NP on 3rd line therapy> death$ [62, 63] 0.489 (0.458-0.520) Beta (485.27, 507.73) 
    
Stage IV, No systemic therapy    
No systemic therapy> No systemic 
therapy 
 
1-sum of other 
probabilities 
 
No systemic therapy > death$ [64] 0.646 (0.616-0.677) Beta (605.07, 330.93) 
    
Progressive Disease (PD)    
PD>PD  
1-sum of other 
probabilities 
 
PD> death$ [65] 
0.908 (0.797-0.977) 
 
Beta (33.58, 3.42) 
    
Undiagnosed> Diagnosed RCC 






0.25 (0.01-0.76) Beta (1.07, 2.65) 
    
Proportion undergoing each 
management option 
   
Management option Source Proportion (n/N) Distribution 
Stage I RCC (T1a)    
Active Surveillance Expert opinion Age Dependent  
Percutaneous ablation [66] 0.024 (77/3158) Beta (77, 3081) 
Open partial nephrectomy [67] 0.145 (235/1617) 
Dirichlet (235, 223, 494, 52, 
588, 25) 
Laparoscopic partial nephrectomy [67] 0.138 (223/1617) 
Robotic partial nephrectomy [67] 0.306 (494/1617) 
Open radical nephrectomy [67] 0.032 (52/1617) 
Laparoscopic radical nephrectomy [67] 0.364 (588/1617) 
Robotic radical nephrectomy [67] 0.015 (25/1617) 
    
Stage I RCC (T1b)    
Open partial nephrectomy [67] 0.074 (108/1455) 
Dirichlet (108, 21, 81, 151, 
1040, 54) 
Laparoscopic partial nephrectomy [67] 0.014 (21/1455) 
Robotic partial nephrectomy [67] 0.056 (81/1455) 
Open radical nephrectomy [67] 0.104 (151/1455) 
Laparoscopic radical nephrectomy [67] 0.715 (1040/1455) 
Robotic radical nephrectomy [67] 0.037 (54/1455) 
    
Stage II RCC    




Laparoscopic partial nephrectomy [67] 0.003 (4/1419) 
Dirichlet (27, 4, 16, 580, 
766, 26) 
Robotic partial nephrectomy [67] 0.011 (16/1419) 
Open radical nephrectomy [67] 0.409 (580/1419) 
Laparoscopic radical nephrectomy [67] 0.540 (766/1419) 
Robotic radical nephrectomy [67] 0.018 (26/1419) 
    
Stage III RCC    
Open radical nephrectomy 
Expert Opinion 
0.51 Uniform (0.35, 0.65) 
Laparoscopic or robotic radical 
nephrectomy 
0.49 Uniform (0.65, 0.35) 
    
Stage IV RCC    
Cytoreductive nephrectomy [68-74] 0.37 (18,831/50,895) Beta (18831, 32064) 
Metastasectomy [57, 75] 
0.17 (107/623)~~ 
 
Beta (107, 516) 
Palliative radiotherapy 
for bone pain 
[76, 77] 0.12 (137/1108) Beta (137,971) 
Proportion of patients receiving no 
systemic therapy 
[63, 78-83] 0.28 (104/365) 
 
Beta (104, 261) 
Proportion receiving first line therapy [83] 0.72 (261/365) Beta (261, 104) 
Proportion of individuals on first line 
therapy who receive sunitinib 
[84] 0.43 (527/1229) Beta (527, 702) 
Proportion of individuals on first line 
therapy who receive second line 
therapy 
[83] 0.47 (123/261) Beta (123, 138) 
Proportion of individuals on second 
line therapy who receive third line 
therapy 
[83] 0.33 (41/123) Beta (41, 82) 
    
Unit costs    
Parameter Source Mean (SE) or (IQR) Distribution 
Screening costs    
Invitation (clerical staff time, postage 
and stationery, cost of obtaining 
patient details, office space and 
equipment) 
[21] 
£1.94 [€2] (0.49) 
 
Gamma (16, 0.12) 
 
 
Technician performed ultrasound [21] 
£37.53 [€47] (9.38) 
 
Gamma (16, 2.35) 
CT Abdomen & Pelvis with contrast [26] £115 [145€] (£88-£134) Gamma (10.59, 10.66) 
    
Assessment    
Clinical biochemistry [26] 




£3 [€4] (£2-£4) 
 
Gamma (4.08, 0.77) 
Phlebotomy [26] 
£3 [€4] (£2-£4) 
 
Gamma (4.08, 0.77) 
Histopathology [26] 
£31 [€39] (£15-£36) 
 
Gamma (2.66, 10.25) 
CT chest with contrast [26] 
£102 [€129] (£71-£135) 
 
Gamma (4.70, 22.77) 
CT of three areas with contrast [26] 
£121 [€153] (£88-£139) 
 
Gamma (9.01, 12.86) 
CT brain [26] 
102 [€129] (£71-£135) 
 
Gamma (4.70, 22.77) 
Outpatient renal biopsy [26] 
£158 [€199] (£125-£194) 
 
Gamma (9.72, 16.72) 
Urology outpatient clinic [26] 
£ 105.19 [€133] (10.52) 
 
Gamma (100, 1.05) 
Oncology clinic [26] 
£151 [€191] (£125-£194) 
 
Gamma (9.72, 16.72) 
MDT discussion [26] 
£107 [€135] (£71-£131) 
 




    
 
Management 
   
Percutaneous Cryoablation [26] 
£5,372 [€6,783]  
(£3,444-£6,563) 
 
Gamma (4.67, 1113.35) 
Percutaneous, Microwave or 
Radiofrequency Ablation 
[26] 
£2,952 [€3,727]  
(£1,706-£3,559) 
 
Gamma (3.66, 756.08) 
Laparoscopic nephrectomy (partial or 
radical) Cost of surgery and health 
care costs over one year 
[85] 
£6,581 [€8,309] 
 (£6,001- £7123) 
 
Gamma (62.33, 105.59) 
 
Open nephrectomy (partial or radical) 
Cost of surgery and health care costs 
over one year 
[85] 
£8,021 [€10,127]  
(£7,000-£8,946) 
 
Gamma (30.55, 262.55) 
 
Robotic nephrectomy (partial or 
radical) 
Cost of surgery and health care costs 
over one year 
[85] 
£6,534 [€8,250]  
(£5,972-£7,059) 
 
Gamma (65.32, 100.03) 
 
Cytoreductive nephrectomy 
Cost of surgery and health care costs 




£9,938 [€12,548]  
(993.8) 
 
Gamma (100, 99.38) 
Metastasectomy for thoracic 
metastases 
[26] 
£6,514 [€8,225]  
(£4,973-£7,655) 
 
Gamma (10.08, 637.65) 
Metastasectomy for abdominal 
metastases 
[26] 
£4,101 [€5,178]  
(£2,538-£5,345) 
 
Gamma (3.57, 1160.30) 
Radiotherapy (preparation and 
delivery) 
[26] 
£388 [€490]  
(£279-£483) 
 
Gamma (6.34, 61.79) 
    
Annual drug costs    






























Contact with the health services due 





Beta (100, 16.22) 
Contact with the health services due 





Beta (100, 21.44) 
    
Summary costs for health states    






Incidental congenital renal anomaly  £105  
  [€133]  



















    
Metastasis free Stage I-III  £0  
Undiagnosed RCC  £0  
    












    


































    
    
Utilities    
Parameter Source Mean Distribution 
Screening Ultrasound Assumption 
1 
Varied in sensitivity 
analysis 
Constant 
No cancer Assumption 1 Constant 
Undiagnosed Cancer Assumption 1 Constant 
Newly diagnosed Stage I T1a  
Clinical expert 
opinion based 
on [22, 93] 
 
0.934$$ Beta (5.64, 0.40) 
Newly diagnosed I T1b 0.934$$ Beta (5.64, 0.40) 
Newly diagnosed Stage II 0.869## Beta (12.28, 1.86) 
Newly diagnosed Stage III 0.869## Beta (12.28, 1.86) 
Metastasis free Stages I-III 1 Constant 
    
False positive Stage I T1a 
Assumption 
0.934$$ Beta (5.64, 0.40) 
False positive Stage I T1b 0.934$$ Beta (5.64, 0.40) 
False positive Stage II 0.869## Beta (12.28, 1.86) 
    
Stage IV, NP on 1st line therapy [94-98] 0.78 Beta (1337.7, 377.3) 
Stage IV, NP on 2nd line therapy [77] 0.70 Beta (29.3, 12.56) 
Stage IV, NP on 3rd line therapy 
Assumption 
based on [77] 
0.70 Beta (29.3, 12.56) 
Stage IV, NST [77] 0.69 Beta (500.31, 222.68) 
Progressive Disease [77] 0.61 Beta (441.03, 281.97) 
Terminal, RCC Death and Non-RCC 
Death 
Assumption 0 Constant 
~Small or atrophic kidneys, aplasia, dysplasia, duplication or horseshoe kidney 463 




#Proportions of those stage I 465 
**Relative survival, therefore this was converted to absolute survival using the age dependent probability of 466 
background mortality (see Supplement for details). 467 
$Overall survival data was utilised to calculate the transition probability from each health state to death. This 468 
value was subsequently adjusted based on known age dependent background mortality to derive the 469 
transition probability for RCC death 470 
~~It was assumed 28.8% (17/59) of individuals undergo surgical management for thoracic metastases and 471 
71.2% (42/59) for abdominal metastases [75]. 472 
$$Equivalent to a utility of 0.737 for 3 months and a utility of 1 for 9 months 473 





Table 2: Baseline results  476 
The incremental costs (cost of screening and treatment), quality adjusted life years (QALYs) 477 
and incremental cost-effectiveness ratio (ICER) per person screened is shown for each age 478 
and sex. 479 
 480 
 481 
 Males Females 















Incremental costs £47.06 £45.69 £44.55 £47.61 £46.99 £46.56 
Incremental QALYs 0.00155 0.00205 0.00246 0.000809 0.000937 0.00125 




Table 3: Results of the two-way sensitivity analysis of age, sex, prevalence of RCC and cost of screening ultrasound 482 
The incremental cost-effectiveness ratio (ICER) is shown for each age and sex. Values are highlighted in green if the ICER < £20,000/QALY, 483 
amber if the ICER £20,000-£30,000/QALY and red if the ICER > £30,000/QALY.  484 
485 
 Males Females 
Prevalence 40 years 50 years 60 years 40 years 50 years 60 years 
0.0005 £79,384 £99,763 £134,251 £77,526 £93,379 £123,795 
0.001 £41,969 £49,599 £69,003 £38,733 £44,318 £57,667 
0.0015 £30,359 £31,496 £46,545 £25,266 £28,901 £37,799 
0.002 £20,832 £25,143 £33,320 £18,935 £22,306 £29,603 
0.0025 £14,949 £18,784 £26,377 £14,592 £18,170 £22,058 
0.003 £12,969 £15,546 £21,163 £12,212 £14,615 £19,429 
0.0035 £9,961 £12,046 £16,676 £10,474 £12,308 £15,710 
0.004 £9,154 £11,830 £15,644 £8,920 £10,399 £13,846 
0.0045 £7,803 £9,990 £14,633 £7,533 £8,897 £11,548 
0.005 £6,862 £8,433 £12,774 £6,611 £7,957 £10,285 
0.0055 £6,209 £8,232 £11,438 £6,152 £7,413 £9,151 
0.006 £5,651 £7,786 £10,123 £5,716 £6,863 £8,862 
       
Cost of US       
£70 £47,863 £34,319 £34,000 £91,772 £85,491 £69,092 
£60 £40,587 £31,717 £29,317 £81,603 £76,915 £59,227 
£50 £35,309 £26,187 £24,134 £68,069 £62,299 £45,981 
£40 £29,199 £21,161 £18,443 £57,431 £52,414 £38,759 
£30 £23,165 £18,479 £16,061 £45,740 £42,234 £28,754 
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